Method of treating patients with hepatorenal syndrome type 1
AssigneeMallinckrodt Pharmaceuticals Ireland Limited
InventorsKhurram Jamil, Stephen Chris Pappas, Peter Teuber
Life of this patent
Estimating the term…
Loading patent…
AssigneeMallinckrodt Pharmaceuticals Ireland Limited
InventorsKhurram Jamil, Stephen Chris Pappas, Peter Teuber
Estimating the term…
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include administering a dose of terlipressin to the patient if the patient has a baseline model end stage liver disease (MELD) score<35, the patient has a serum creatinine (SCr)<5 mg/dl, the patient has an ACLF Grade<3, or a combination thereof and/or monitoring the patient's oxygenation level (SpO2) before and during treatment with the terlipressin.
A method of treating a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
A method of improving the liver-transplant-free survival in a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
A method of increasing the 90-day survival rate in a patient who has type-1 hepatorenal syndrome and at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
A method of treating a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
Dependencies are inferred from the claim text.